EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms

Belinda L Sun iD, Hongxu Ding, Xiaoguang Sun

American Journal of Clinical Pathology · 03.06.2025 · 163 (6) · 804-814

DOI: 10.1093/ajcp/aqaf013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 04.03.2025. Verfasst von Belinda L Sun und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The classification of neuroendocrine neoplasms has evolved significantly. In the current World Health Organization (WHO) classification, well-differentiated grade 3 neuroendocrine tumors (G3-NETs) are distinguished from poorly-differentiated neuroendocrine carcinomas (NECs) based on morphology despite using the same proliferation indices, which poses diagnostic challenges. This review aims to assist pathologists in making an accurate diagnosis, which is crucial for patient management as G3-NETs and NECs have different prognoses and chemotherapy responses.

Methods

A literature review and meta-analyses were conducted to summarize current knowledge of G3-NETs and NECs, focusing on histopathologic and genetic characteristics.

Results

Grade 3 neuroendocrine tumors and NECs are distinct entities with differences in histopathology, genetics, and clinical presentations. Grade 3 neuroendocrine tumors have a lower Ki-67 proliferation index and tumor mutational burden compared to NECs. Distinct gene mutations and pathways have been identified in G3-NETs and NECs, offering potential for developing a diagnostic gene panel. The 2022 WHO classification recognizes the use of immunohistochemistry for somatostatin receptors 2/5, TP53, Rb, Menin, P27, ATRX, and DAXX to distinguish G3-NETs and NECs. In particular, TP53 and ATRX immunohistochemistry may be useful in routine diagnostics.

Conclusions

Specific immunohistochemistry and genetic tests should be developed and incorporated into the classification to reliably distinguish G3-NETs from NECs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsCarcinoma, NeuroendocrineHumansNeoplasm GradingBiomarkers, TumorDiagnosis, DifferentialMutationImmunohistochemistry

Stichwörter der Autor:innen

neuroendocrine neoplasmpoorly-differentiated neuroendocrine carcinomawell-differentiated grade 3 neuroendocrine tumor

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States.
  • College of Pharmacy, University of Arizona, Tucson, AZ, United States.
  • Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States.

ORCID-Profile: Belinda L Sun

Zitieren

APA

Sun, B. L., Ding, H., & Sun, X. (2025). Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms. American Journal of Clinical Pathology, 163(6), 804-814. https://doi.org/10.1093/ajcp/aqaf013

Vancouver

Sun BL, Ding H, Sun X. Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms. American Journal of Clinical Pathology. 2025;163(6):804-814. doi:10.1093/ajcp/aqaf013

BibTeX
@article{Sun2025,
  author = {Sun, Belinda L and Ding, Hongxu and Sun, Xiaoguang},
  title = {Histopathologic and genetic distinction of well-differentiated grade 3 neuroendocrine tumor versus poorly-differentiated neuroendocrine carcinoma in high-grade neuroendocrine neoplasms},
  journal = {American Journal of Clinical Pathology},
  year = {2025},
  volume = {163},
  number = {6},
  pages = {804--814},
  doi = {10.1093/ajcp/aqaf013}
}
Kostenlos starten →